FansUnite Entertainment to Present at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22, 2021

FansUnite Entertainment Inc. (CSE:FANS)(OTCQB:FUNFF) ("FansUnite" or the "Company"), today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22 at 3:00 PM EST. Scott Burton, CEO of FansUnite will be hosting the presentation and answering questions from investors

To access the live presentation, please use the following information:

Planet MicroCap Showcase: VIRTUAL 2021

Date: Thursday, April 22, 2021

Time: 3:00 PM Eastern Time (12:00 PM Pacific Time)

Webcast: https://www.webcaster4.com/Webcast/Page/2059/40981

If you would like to book 1on1 investor meetings with FansUnite, and to watch FansUnite's presentation, please make sure you are registered for the virtual event here: https://planetmicrocapshowcase.com/signup

1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

The Planet MicroCap Showcase: VIRTUAL website is available here: https://planetmicrocapshowcase.com/

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://planetmicrocapshowcase.com/agenda

News Compliments of Accesswire

About FansUnite Entertainment Inc.

FansUnite is a sports and entertainment company, focusing on technology related to regulated and lawful online gaming and other related products. The principal business is operating the FansUnite Sportsbook and the website of its wholly-owned subsidiary, McBookie Limited, offering online gaming services to the UK market. FansUnite is also a provider of technology solutions, products and services in the gaming and entertainment industry and looks to acquire technology platforms and assets with high-growth potential in new or developing markets.

About SNN.Network

SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create YOUR own watchlist and screen for ideas YOU'RE interested in; find out about investor conferences YOU want to attend - all here on SNN.Network.

If you would like to attend the Planet MicroCap Showcase, please register here: https://planetmicrocapshowcase.com/signup

CONTACT:

Prit Singh, Investor Relations at FansUnite
ir@fansunite.com
(905) 510-7636

Scott Burton, Chief Executive Officer of FansUnite
scott@fansunite.com

Darius Eghdami, President of FansUnite
darius@fansunite.com

SOURCE:FansUnite via SNN Network

View source version on accesswire.com:
https://www.accesswire.com/641286/FansUnite-Entertainment-to-Present-at-the-Planet-MicroCap-Showcase-VIRTUAL-on-Thursday-April-22-2021

News Provided by ACCESSWIRE via QuoteMedia

FansUnite CSE:FANS Emerging Tech Investing

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Syntheia Announces Establishment of Advisory Board and Appointment of Travel Industry Expert, Mr. John Kirk

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is pleased to announce the establishment of its new Advisory Board. The Advisory Board will collaborate with management and the board of directors to enhance the Company's strategic direction, provide expert guidance on its commercial initiatives, offer industry insights, and shape and accelerate innovations.

As the inaugural member of the Advisory Board, Syntheia welcomes Mr. John Kirk, a leader in the travel industry. The travel sector represents a potentially significant growth market for the Company's technology.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Syntheia Enhances Inbound Customer Calls with AI-Powered Virtual Assistants, Positively Impacts Sales and Customer Satisfaction

Syntheia Corp. ("Syntheia" or the "Company") (Syntheia.ai), CSE SYAI, Syntheia, a Canadian leader in conversational AI SaaS, is transforming customer service by delivering an innovative solution that uses natural language processing (NLP) to handle inbound telephone calls with virtual assistants. Since its beta launch in June 2023, Syntheia has processed over 750,000 conversations, bringing new levels of efficiency and engagement to businesses in diverse industries.

Companies like Georgetown Hyundai, Palmieri Furniture, Campio Furniture, and Pay N Go have all embraced Syntheia's platform, highlighting its positive impact on sales and customer satisfaction.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Zero Candida Technologies Inc. Opens the Market

Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.

Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.

Please refer to the Company's website here.

MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
victoria@zero-candida.com
416-706-0332

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

FansUnite Entertainment to Present at the Planet MicroCap Showcase: VIRTUAL on Thursday, April 22, 2021

Latest News

Latest Press Releases

Related News

TOP STOCKS